Modern Authentication of Pharmaceuticals Act of 2022

Modern Authentication of Pharmaceuticals Act of 2022

This bill requires each dose of a pharmaceutical product that is a controlled substance and that is taken orally in solid form (i.e., pills) to include a physical chemical identifier. The bill applies to products manufactured on or after January 1, 2026.

Bill 117 HR 7653, also known as the Modern Authentication of Pharmaceuticals Act of 2022, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to enhance the security and authenticity of pharmaceutical products in order to protect consumers from counterfeit or substandard medications.

The bill proposes the implementation of modern authentication technologies, such as track-and-trace systems and unique identifiers, to ensure that pharmaceutical products can be easily verified and traced throughout the supply chain. This would help to prevent the distribution of counterfeit drugs and improve the overall safety and effectiveness of medications.

Additionally, the bill includes provisions for increased oversight and regulation of pharmaceutical manufacturers, distributors, and other entities involved in the production and distribution of medications. This would help to ensure that all parties involved in the pharmaceutical supply chain are held accountable for the quality and authenticity of the products they produce and distribute. Overall, the Modern Authentication of Pharmaceuticals Act of 2022 aims to strengthen the security and integrity of the pharmaceutical supply chain in order to protect consumers and improve public health outcomes. It is currently being reviewed by Congress and may be subject to amendments or revisions before being passed into law.